JP2020537649A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537649A5
JP2020537649A5 JP2020520804A JP2020520804A JP2020537649A5 JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5 JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020537649 A5 JP2020537649 A5 JP 2020537649A5
Authority
JP
Japan
Prior art keywords
seq
sequence
heavy chain
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020520804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537649A (ja
JP7374891B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/055733 external-priority patent/WO2019075417A1/en
Publication of JP2020537649A publication Critical patent/JP2020537649A/ja
Publication of JP2020537649A5 publication Critical patent/JP2020537649A5/ja
Priority to JP2023183034A priority Critical patent/JP2024012366A/ja
Application granted granted Critical
Publication of JP7374891B2 publication Critical patent/JP7374891B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520804A 2017-10-14 2018-10-12 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法 Active JP7374891B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023183034A JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
US62/572,467 2017-10-14
PCT/US2018/055733 WO2019075417A1 (en) 2017-10-14 2018-10-12 CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023183034A Division JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Publications (3)

Publication Number Publication Date
JP2020537649A JP2020537649A (ja) 2020-12-24
JP2020537649A5 true JP2020537649A5 (enExample) 2021-07-26
JP7374891B2 JP7374891B2 (ja) 2023-11-07

Family

ID=64110112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520804A Active JP7374891B2 (ja) 2017-10-14 2018-10-12 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗cd71抗体による薬物コンジュゲート及びこの使用の方法

Country Status (36)

Country Link
US (3) US20190111150A1 (enExample)
EP (2) EP3691692B8 (enExample)
JP (2) JP7374891B2 (enExample)
KR (4) KR20230070046A (enExample)
CN (1) CN111278467B (enExample)
AR (1) AR115178A1 (enExample)
AU (1) AU2018346969A1 (enExample)
BR (1) BR112020007302B1 (enExample)
CA (1) CA3077730A1 (enExample)
CL (1) CL2020000977A1 (enExample)
CO (1) CO2020005685A2 (enExample)
CR (1) CR20200206A (enExample)
CY (1) CY1123968T1 (enExample)
DK (1) DK3691692T3 (enExample)
DO (1) DOP2023000150A (enExample)
EC (1) ECSP20025198A (enExample)
ES (1) ES2864013T3 (enExample)
HR (1) HRP20210436T8 (enExample)
HU (1) HUE054037T2 (enExample)
IL (1) IL273586A (enExample)
LT (1) LT3691692T (enExample)
MA (1) MA50752B1 (enExample)
MD (1) MD3691692T2 (enExample)
MX (1) MX2020003723A (enExample)
PE (1) PE20210125A1 (enExample)
PH (1) PH12020550417A1 (enExample)
PL (1) PL3691692T3 (enExample)
PT (1) PT3691692T (enExample)
RS (1) RS61596B1 (enExample)
RU (2) RU2771292C2 (enExample)
SG (1) SG11202003378WA (enExample)
SI (1) SI3691692T1 (enExample)
SM (1) SMT202100184T1 (enExample)
TW (2) TW202330039A (enExample)
UY (1) UY37931A (enExample)
WO (1) WO2019075417A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
CN110809583A (zh) 2017-06-07 2020-02-18 瑞泽恩制药公司 用于内化酶的组合物和方法
PH12020550417A1 (en) * 2017-10-14 2021-04-12 Abbvie Inc Anti-cd71 activatable antibody drug conjugates and methods of use thereof
KR20200118151A (ko) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
MX2020012350A (es) 2018-05-17 2021-01-29 Regeneron Pharma Anticuerpos anti-cd63, conjugados y usos de estos.
MX2022012635A (es) * 2020-04-08 2023-01-11 Aliada Therapeutics Inc Composiciones y métodos para distribución de barrera hematoencefálica.
KR20220166814A (ko) 2020-04-09 2022-12-19 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체를 함유하는 조성물
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
AU2022388735A1 (en) 2021-11-09 2024-05-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
JP2025528052A (ja) * 2022-07-29 2025-08-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 脳及び筋肉へのトランスフェリン受容体(tfr)媒介送達のための組成物及び方法
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025133132A1 (en) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Novel anti-tfr1 (cd71) antibodies for cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001513A1 (fr) 1986-08-28 1988-03-10 Teijin Limited Complexe d'anticorps cytocide et procede de production
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
AU2006284651C1 (en) 2005-08-31 2013-09-12 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
BRPI0820270A2 (pt) * 2007-11-07 2015-06-16 Celldex Therapeutics Inc Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
WO2010081173A2 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8765916B2 (en) * 2009-04-29 2014-07-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
CA2826186C (en) * 2011-02-01 2020-08-04 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
DK2809683T3 (en) * 2012-01-31 2018-12-10 Sbi Biotech Co Ltd ANTI-phospholipase D 4 ANTIBODY
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
PT3088419T (pt) * 2013-12-25 2019-01-11 Daiichi Sankyo Co Ltd Conjugado de anticorpo anti-trop2-fármaco
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
PH12020550417A1 (en) * 2017-10-14 2021-04-12 Abbvie Inc Anti-cd71 activatable antibody drug conjugates and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2020537649A5 (enExample)
HRP20210436T1 (hr) Konjugati protutijela s lijekom koje može aktivirati protutijelo protiv cd71 i postupci njihove upotrebe
JP2022064924A5 (enExample)
JP2020500016A5 (enExample)
JP2020506900A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2020524661A5 (enExample)
MX2025004236A (es) Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana)
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
HRP20241563T1 (hr) Postupak liječenja ili ublažavanja metaboličkih poremećaja primjenom agonista glp-1 receptora konjugiranih na antagoniste želučanog inhibitornog peptidnog receptora (gipr)
JP2024016177A5 (enExample)
JP2019504032A5 (enExample)
EP4588940A3 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
RU2015101803A (ru) Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2020500538A5 (enExample)
JP2020519643A5 (enExample)
PE20140133A1 (es) Nuevas proteinas de union a antigenos
ME02807B (me) HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE
IL257281A (en) Anti-pd-1 antibodies and methods of using them
JP2015120706A5 (enExample)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
NZ603972A (en) Anti-fgfr2 antibodies
RU2010116152A (ru) Антитело против рецептора il-6
RU2017104815A (ru) Молекулы со специфичностью в отношении cd79 и cd22